期刊文献+

调脂增寿汤治疗血脂异常的对照研究

Comparative study of tiaozhi zengshou tang in treatment of dyslipidaemia
下载PDF
导出
摘要 目的:观察调脂增寿汤对血脂异常患者的临床疗效。方法:将93例血脂异常患者随机分为中药组31例,给予调脂增寿汤;西药组30例,给予美百乐镇;中西药组32例,给予美百乐镇和调脂增寿汤。各治疗8周,观察其疗效、血脂变化及不良反应情况。结果:中药组的总有效率为81%。中药组三酰甘油由(2.59±1.64)mmol/L降至(1.56±0.72)mmol/L、血清总胆固醇由(5.3±1.71)mmol/L降至(4.35±0.85)mmol/L,治疗前后比较均有显著差异(t=2.51,2.77,P<0.05),与西药组差异无显著性(P>0.05);中药组高密度脂蛋白胆固醇由(1.37±0.36)mmol/L升至(1.52±0.18)mmol/L,治疗前后比较,差异有显著性意义(t=2.45,P<0.05);中药组不良反应发生率低,与西药组比较,差异有显著性意义(P<0.05)。结论:调脂增寿汤治疗血脂异常临床疗效确切且不良反应发生率低,具有推广价值。 AIM:To observe the clinical curative effect of tiaozhi zengshou tang in patients with dyslipidaemia. METHODS: Ninety three patients with dyslipidaemia were randomized into three groups: 31 patients in traditional Chinese medicine(TCM) group that receiving tiaozhi zengshou tang,30 patients in western medicine group that receiving Mevalotin,and 32 patients in combined treatment group that receiving tiaozhi zengshou tang and Mevalotin. The therapeutic course for each group was 8 weeks. The effect in regulating blood lipids and adverse effect in patients were observed. RESULTS: The total effective rate of the TCM was 81%.Tiacylglycerol (TG) and total cholesterol(TC) in the TCM group were decreased from (2.59±1.64) mmol/L to(1.56±0.72) mmol/L,from (5.3±1.71) mmol/L to (4.35±0.85) mmol/L respectively, which indicated significant difference before and after treatment (t=2.51, 2.77,P< 0.05). As compared with western medicine group,there was no significant difference(P >0.05); The level of high density lipoprotein cholesterol was significantly increased from (1.37±0.36) mmol/L to (1.52±0.18) mmol/L in the TCM group, which showed significant difference before and after treatment(t=2.45,P< 0.05).The adverse effect of the TCM group occurred less than that of the western medicine group, which showed significant difference (P< 0.05). CONCLUSION:Tiaozhi zengshou tang has definite curative effect in patients with dyslipidaemia and has few adverse effects.
出处 《中国临床康复》 CSCD 2004年第18期3554-3555,共2页 Chinese Journal of Clinical Rehabilitation
  • 相关文献

参考文献11

  • 1The Scandinavian Simvastatin Surrival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Surrival Study(4S). Lancet 1994, 344:1383 -9
  • 2Downs JR, Clearfield M, Whitney E, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615 - 22
  • 3Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholest
  • 4Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safety of simvaststin 80 mg/day in hypercholesterolemia patients. An J Cardiol 1998; 82 (3): 311 - 6
  • 5The long term Intervention with Pravastatin in Ischemic Disease(LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and abroad range initial cholesterol levels. N Engl J Med 1998; 339(
  • 6陆国平,戚文航.冠心病的一级预防[J].新医学,2000,31(1):13-14. 被引量:9
  • 7方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067
  • 8刘国仗,胡大一,陶萍,诸骏仁,郭林妮,郭静萱,游凯.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11. 被引量:1440
  • 9沈丽华 柯开富 李作汉.家族聚集性脑梗死发病与低密度脂蛋白胆固醇的相关性[J].中国临床康复,2003,7(31):4246-7.
  • 10尹巧香,赵玉生,陈真.代谢综合征与冠心病及血脂异常的相关性[J].中国临床康复,2003,7(21):2916-2917. 被引量:38

二级参考文献2

共引文献4510

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部